prof. dr. E. (Edo) Vellenga

Professor

prof. dr. E. (Edo) Vellenga
Telephone:
E-mail:
e.vellenga umcg.nl

Research

  1. 2020
  2. Cruijsen, M., van der Velden, W. J. F. M., de Haan, A. F. J., Klein, S. K., Hoogendoorn, M., Tromp, Y., de Valk, B., van Rees, B., de Boer, F., van der Spek, E., Pruijt, J., Verdonck, L. F., Vellenga, E., Blijlevens, N., van de Loosdrecht, A. A., & Huls, G. (2020). Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. Leukemia & Lymphoma, 61(11), 2752-2755. https://doi.org/10.1080/10428194.2020.1775217
  3. Wester, R., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M. C., Lonergan, S., Palumbo, A., Broijl, A., & Sonneveld, P. (2020). Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere, 4(4), [e370]. https://doi.org/10.1097/HS9.0000000000000370
  4. Dutch-Belgian Hemato-Oncology, Swiss Grp Clinical Canc Res SAKK, Ossenkoppele, G. J., Breems, D. A., Stuessi, G., Van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., ... Lowenberg, B. (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, (7), 1751-1759. https://doi.org/10.1038/s41375-020-0725-0
  5. Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Diez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., Sekeres, M. A., Falantes, J. F., Arrizabalaga, B., Salvi, F., Giai, V., Vyas, P., Bowen, D., Selleslag, D., DeZern, A. E., ... List, A. F. (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 382(2), 140-151. https://doi.org/10.1056/NEJMoa1908892
  6. Steensma, D. P., Fenaux, P., Van Eygen, K., Raza, A., Santini, V., Germing, U., Font, P., Diez-Campelo, M., Thepot, S., Vellenga, E., Patnaik, M. M., Jang, J. H., Varsos, H., Bussolari, J., Rose, E., Sherman, L., Sun, L., Wan, Y., Dougherty, S., ... Platzbecker, U. (2020). Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (1), JCO2001895. https://doi.org/10.1200/JCO.20.01895
  7. 2019
  8. PETHEMA, HOVON, PALG, GATLA cooperative groups, Sobas, M., Rodriguez-Veiga, R., Vellenga, E., Paluszewska, M., De la Serna, J., García-Álvarez, F., Gil, C., Brunet, S., Bergua, J., González-Campos, J., Ribera, J. M., Tormo, M., González, M., Fernández, I., Benavente, C., González-Sanmiguel, J. D., Esteve, J., Pérez-Encinas, M., ... Montesinos, P. (2019). Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. European Journal of Haematology. https://doi.org/10.1111/ejh.13346
  9. Wester, R., van der Holt, B., Asselbergs, E., Zweegman, S., Kersten, M. J., Vellenga, E., van Marwijk Kooy, M., de Weerdt, O., Minnema, M., Lonergan, S., Palumbo, A., Lokhorst, H., Broijl, A., & Sonneveld, P. (2019). Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial. Haematologica, 104(11), 2265-2273. https://doi.org/10.3324/haematol.2018.205476
  10. Berger, G., Gerritsen, M., Yi, G., Koorenhof-Scheele, T. N., Kroeze, L. I., Stevens-Kroef, M., Yoshida, K., Shiraishi, Y., van den Berg, E., Schepers, H., Huls, G., Mulder, A. B., Ogawa, S., Martens, J. H. A., Jansen, J. H., & Vellenga, E. (2019). Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. Blood, 3(20), 3111-3122. https://doi.org/10.1182/bloodadvances.2019000518
  11. Wester, R., Zweegman, S., Van der Holt, B., Jose, K. M., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M., Lonergan, S., Palumbo, A., Broijl, A., & Sonneveld, P. (2019). Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial. Clinical lymphoma myeloma & leukemia, 19(10), E220-E221. https://doi.org/10.1016/j.clml.2019.09.367
  12. Labrador, J., Luño, E., Vellenga, E., Brunet, S., González-Campos, J., Chillón, M. C., Holowiecka, A., Esteve, J., Bergua, J., González-Sanmiguel, J. D., Gil, C., Tormo, M., Salamero, O., Manso, F., Fernández, I., de laSerna, J., Moreno, M-J., Pérez-Encinas, M., Krsnik, I., ... Montesinos, P. (2019). Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia & Lymphoma, 60(5), 1146-1155. https://doi.org/10.1080/10428194.2018.1522438
  13. Huls, G., Chitu, D. A., Havelange, V., Jongen-Lavrencic, M., van de Loosdrecht, A. A., Biemond, B. J., Sinnige, H., Hodossy, B., Graux, C., van Marwijk Kooy, R., de Weerdt, O., Breems, D., Klein, S., Kuball, J., Deeren, D., Terpstra, W., Vekemans, M-C., Ossenkoppele, G. J., Vellenga, E., & Löwenberg, B. (2019). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood, 1457-1464. https://doi.org/10.1182/blood-2018-10-879866
  14. Yi, G., Wierenga, A. T. J., Petraglia, F., Narang, P., Janssen-Megens, E. M., Mandoli, A., Merkel, A., Berentsen, K., Kim, B., Matarese, F., Singh, A. A., Habibi, E., Prange, K. H. M., Mulder, A. B., Jansen, J. H., Clarke, L., Heath, S., van der Reijden, B. A., Flicek, P., ... Martens, J. H. A. (2019). Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes. Cell reports, 26(4), 1059-1069.e6. https://doi.org/10.1016/j.celrep.2018.12.098
  15. 2018
  16. Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Diez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., Sekeres, M. A., Falantes, J. F., Arrizabalaga, B., Salvi, F., Giai, V., Vyas, P., Bowen, D., Selleslag, D., DeZern, A. E., ... List, A. F. (2018). The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 132. https://doi.org/10.1182/blood-2018-99-110805
  17. Huls, G., Lowenberg, B., van de Loosdrecht, A. A., Janssen, J. J. W. M., Jongen-Lavrencic, M., Raaijmakers, M., Wouters, B., Von dem Borne, P. A., Kuball, J., Biemond, B. J., Van Gelder, M., van der Velden, W. J. F. M., de Weerdt, O., van Marwijk Kooy, R., Klein, S., van der Poel, M., van Rhenen, A., Jong, J. J. M. D., Valk, P., ... Ossenkoppele, G. (2018). Richtlijn Acute promyelocytenleukemie (APL): richtlijnen voor diagnostiek en behandeling. Nederlands Tijdschrift voor Hematologie, 15(8), 396-401.
  18. Janssen, J. J. W. M., te Boekhorst, P. A. W., Posthuma, E. F. M., Klein, S. K., Hoogendoorn, M., de Waal, T. T., Falkenburg, J. H. F., Biemond, B. J., van der Reijden, B. A., Bos, G. M. J., Petersen, E. J., Blijlevens, N. M. A., Smit, W. M., Verhoef, G. E. G., Vellenga, E., Thielen, N., Cornelissen, J. J., Ossenkoppele, G. J., & Westerweel, P. E. (2018). Achtergronden bij de richtlijn voor de behandeling van chronische myeloïde leukemie anno 2018: Deel 3: Stoppen van de behandeling, beleid bij zwangerschap, studies en therapie-aanbevelingen. Nederlands Tijdschrift voor Hematologie, 15(7), 326-335.
  19. Janssen, J. J. W. M., te Boekhorst, P. A. W., Posthuma, E. F. M., Klein, S. K., Hoogendoorn, M., de Waal, T. T., Falkenburg, J. H. F., Biemond, B. J., van der Reijden, B. A., Bos, G. M. J., Petersen, E. J., Blijlevens, N. M. A., Smit, W. M., Verhoef, G. E. G., Vellenga, E., Thielen, N., Cornelissen, J. J., Ossenkoppele, G. J., & Westerweel, P. E. (2018). Achtergronden bij de richtlijn voor de behandeling van chronische myeloïde leukemie anno 2018: Deel 2: Het belang van responsmijlpalen, monitoring en mutaties en de behandeling van gevorderde CML-fasen. Nederlands Tijdschrift voor Hematologie, 15(6), 276-284.
  20. Janssen, J. J. W. M., te Boekhorst, P. A. W., Posthuma, E. F. M., Klein, S. K., Hoogendoorn, M., de Waal, T. T., Falkenburg, J. H. F., Biemond, B. J., van der Reijden, B. A., Bos, G. M. J., Petersen, E. J., Blijlevens, N. M. A., Smit, W. M., Verhoef, G. E. G., Vellenga, E., Thielen, N., Cornelissen, J. J., Ossenkoppele, G. J., & Westerweel, P. E. (2018). Achtergronden bij de richtlijn voor de behandeling van chronische myeloïde leukemie anno 2018: Deel 1: Diagnostiek, behandeling en bijwerkingenmanagement. Nederlands Tijdschrift voor Hematologie, 15(5), 218-228.
  21. Singh, A. A., Petraglia, F., Nebbioso, A., Yi, G., Conte, M., Valente, S., Mandoli, A., Scisciola, L., Lindeboom, R., Kerstens, H., Janssen-Megens, E. M., Pourfarzad, F., Habibi, E., Berentsen, K., Kim, B., Logie, C., Heath, S., Wierenga, A. T. J., Clarke, L., ... Martens, J. H. A. (2018). Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 9(39), 25647-25660. https://doi.org/10.18632/oncotarget.25429
  22. Berger, G., Kroeze, L. I., Koorenhof-Scheele, T. N., de Graaf, A. O., Yoshida, K., Ueno, H., Shiraishi, Y., Miyano, S., van den Berg, E., Schepers, H., van der Reijden, B. A., Ogawa, S., Vellenga, E., & Jansen, J. H. (2018). Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. Blood, 131(16), 1846-1857. https://doi.org/10.1182/blood-2017-09-805879
  23. Craddock, C., Versluis, J., Labopin, M., Socie, G., Huynh, A., Deconinck, E., Volin, L., Milpied, N., Bourhis, J. H., Rambaldi, A., Chevallier, P., Blaise, D., Manz, M., Vellenga, E., Vekemans, M-C., Maertens, J., Passweg, J., Vyas, P., Schmid, C., ... Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK (2018). Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. Journal of Internal Medicine, 283(4), 371-379. https://doi.org/10.1111/joim.12720
  24. Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., ... Sonneveld, P. (2018). Bortezomib before and after high-dose therapy in myeloma: Long-term results from the phase III HOVON-65/GMMGHD-4 trial. Leukemia, 32(2), 383-390. https://doi.org/10.1038/leu.2017.211
  25. Martinez-Cuadron, D., Montesinos, P., Vellenga, E., Bernal, T., Salamero, O., Holowiecka, A., Brunet, S., Gil, C., Benavente, C., Ribera, J. M., Perez-Encinas, M., De la Serna, J., Esteve, J., Rubio, V., Gonzalez-Campos, J., Escoda, L., Amutio, M. E., Arnan, M., Arias, J., ... GATLA Grp (2018). Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia, 32(1), 21-29. https://doi.org/10.1038/leu.2017.178
  26. Petraglia, F., Singh, A. A., Carafa, V., Nebbioso, A., Conte, M., Scisciola, L., Valente, S., Baldi, A., Mandoli, A., Petrizzi, V. B., Ingenito, C., De Falco, S., Cicatiello, V., Apicella, I., Janssen-Megens, E. M., Kim, B., Yi, G., Logie, C., Heath, S., ... Altucci, L. (2018). Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, 9(39), 25630-25646. https://doi.org/10.18632/oncotarget.25428
  27. van de Donk, N. W., van der Holt, B., Minnema, M. C., Vellenga, E., Croockewit, S., Kersten, M. J., von dem Borne, P. A., Ypma, P., Schaafsma, R., de Weerdt, O., Klein, S. K., Delforge, M., Levin, M-D., Bos, G. M., Jie, K-S. G., Sinnige, H., Coenen, J. L., de Waal, E. G., Zweegman, S., ... Lokhorst, H. M. (2018). Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematology, 5(10), E479-E492. https://doi.org/10.1016/S2352-3026(18)30149-2
  28. 2017
Previous 1 2 3 4 5 6 7 8 ...11 Next

ID: 156947